Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Design and Integration of Graphene Fibre Based Antennas for Smart Textiles

GFSMART

Smart textiles that provide a seamless command-oriented user interface and have capable of wireless communication, have become active research field in recent decades with interest of wearable and attractive platforms. Well-known mechanical requirements such as light weight, compactness, and flexibility, that smart components should be invisibly...

Funding Programme
Start Date
End Date
Total Funding
€ 195 455
European Countries Involved

Designing for People with Dementia: designing for mindful self-empowerment and social engagement

MinD

This project aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. People who are affected by Alzheimer’s disease or other dementias often face cognitive, behavioural and psychosocial difficulties, including impairment and degeneration of memory and of perceptions of identity. In a social context, this can...

Funding Programme
Start Date
End Date
Total Funding
€ 549 000
European Countries Involved

Designing the I-Do Service: Facilitating Inclusion and Empowerment of People Living with Dementia through Access to Cultural and Creative Activities

IDoService

This fellowship will co-develop, implement and evaluate the I-Do service to increase the socio-cultural participation and empowerment of people living with mild to moderate stages of dementia (PLWD) through an interdisciplinary engaged research approach that combines service design and psychology with a co-design methodology. This user-friendly...

Funding Programme
Start Date
End Date
Total Funding
€ 212 934
European Countries Involved

Developing Integrated Susceptibility and Conductivity MRI for Next Generation Structural and Functional Neuroimaging

DiSCo MRI SFN

MRI is indispensable in the diagnosis of neurodegenerative diseases. These are poorly understood while their prevalence and socio-economic burden continue to rise. Structural and functional MRI can provide biomarkers for early diagnosis and potential therapeutic intervention. My research vision is to develop novel MRI methods for structural and...

Funding Programme
Start Date
End Date
Total Funding
€ 1 721 726
European Countries Involved

Developing new therapies for Batten disease

BATCure

The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a combined incidence of c.1:100 000. The NCLs are devastating and debilitating genetic disorders that mainly affect children...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 681
European Countries Involved

Dipeptide-Repeat Vaccine to prevent ALS and FTD in C9orf72 mutation carriers

DPR-VAX

Neurodegenerative diseases are triggered by protein aggregation in the CNS, but developing therapies has been challenging. Since key disease mechanisms change during disease progression, halting further neuron loss has not been achieved and may not even improve the symptoms and survival. Causal therapy is most realistic for monogenic disease...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

AmInnovation

Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Disruptive technologies for effectively rehabilitating chronic ambulatory disability

MARSI

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder (stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular...

Funding Programme
Start Date
End Date
Total Funding
€ 2 499 150
European Countries Involved

DNA Damage and Repair and its Impact on Healthy Ageing

Dam2Age

We pioneered an initially highly controversial connection between DNA damage and (accelerated) aging. In the previous ERC grant ‘DamAge’ we reached the stage that (segmental) aging in DNA repair-deficient mice can be largely controlled. The severity of the repair defect determines the rate of segmental aging; the repair pathways affected influence...

Funding Programme
Start Date
End Date
Total Funding
€ 2 251 719
European Countries Involved

DNA rEpair impaired Mice with accElerated Neurodegeneration as Tool to Improve Alzheimer therapeutics

Dementia

Alzheimer’s disease (AD) affects worldwide ~50 million people. Preclinical research relies mainly on transgenic mouse models overexpressing mutant human proteins that are altered in <5% of AD cases (e.g. β-amyloid and tau), however, despite prominent protein aggregates, they fail to show the dramatic neurodegeneration and cognitive decline of patients, indicating that plaques and tangles may not be the only requirement for AD. Age is the most determining factor in AD, but is poorly represented in current AD models.
Generating bona fide mouse models for various human DNA repair syndromes we have disclosed a very strong connection between DNA damage, repair and aging including dramatic neurodegeneration. Within the context of ERC-DamAge we discovered striking parallels in neurodegeneration, progressive cognitive decline and genome-wide expression profiles of repair-deficient Ercc1Δ/- mice and human AD. The similarities in expression profiles are an order of magnitude higher than current AD mouse models. We discovered that nutritional interventions can spectacularly delay neurodegeneration, opening realistic perspectives for combating AD and other neurodegenerative disorders. The primary goal of this application is to complete the characterization of the mouse mutants as a valid model for AD by a detailed quantitative comparison of all RNA classes of relevant brain compartments of Ercc1Δ/- mutants and AD patients. This not only provides the final PoC, but also an unparalleled resource for pathway analysis, target identification and biomarkers for monitoring disease progression and effects of any intervention. This application will be instrumental to facilitate transition to a valid AD model for pharmaceutical companies enabling development of effective medication for prevention and/or therapy. This proposal addresses a huge unmet medical need worldwide, which seriously affects QoL, challenges health care systems, and offers unprecedented socio-economical opportunities.

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Electrophysiological markers of cognitive processes and neuroplasticity in healthy ageing and Alzheimer`s disease

NIBSAD

Ageing of the European population is increasing prevalence of age-related diseases such as Alzheimer’s disease (AD). AD is considered a public health priority due to socio-economic costs and limited efficacy of current pharmacological treatments. Co-registration of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS) is a novelty...

Funding Programme
Start Date
End Date
Total Funding
€ 180 277
European Countries Involved

Elucidating the effects of ageing on the nucleoporin-directed neural cell type-specific nuclear architecture and gene regulation

EAGER

Ageing is one of the most critical risk factors for neurological and psychiatric diseases. However, the biological links between physiological ageing and pathological development are still largely unknown. A solid understanding of the biology of brain ageing will thus be a key to developing the means to treat these diseases. Since neurons in the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 999
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).